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Abstract
Background: Naturally acquired immune responses to Plasmodium falciparum merozoite surface protein 3
(MSP3) and UB05 are implicated in semi immunity in populations living in malaria endemic areas. Thus designing
chimeric malaria vaccine candidates involving MSP-3 and UB05 displayed upon the surface of a phage in its native
form could potentiate their immunogenicity and antigenicity. In this study, we have engineered both MSP3 and UB05
upon the Qβ and assessed their antigenicity with plasma from children living in a high malaria transmission region of
Cameroon.
Methods: The surface of the RNA coliphage Qβ was genetically modified to display three Plasmodium falciparum
derived immunogens including MSP3, UB05 and a chimera of the two UB05-MSP3. The resultant recombinant
phages including QβMSP3, QβUB05 and QβUB05-MSP3 with surface displayed malaria immunogens were
produced after transformation of the E. coli strain HB101. Plasma levels of antigen specific IgG antibody were then
determined in samples from malaria positive and negative children living in a high malaria transmission region of
Cameroon.
Results: To improve yield each recombinant phage was scaled up to 1014 pfu/ml using production strategies
previously optimized in our group. This was significantly higher (P<0.001) relative to the 108 pfu/ml of the wild type
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phage when produced routinely. Conformational integrity of the surface displayed antigens was confirmed in ELISA
assays by testing for the specific recognition of the N and C-terminal parts of both UB05 and MSP3 using the
recombinant QβMSP3, QβUB05 and chimeric QβUB05-MSP3 phages as antigens and the monoclonal antibodies X-
Q38G73-N, X-Q0KGH2-N, X-Q38G73-C, X-Q0KGH2-C targeting the N- and C-terminals of both UB05 and MSP3
respectively. Antigen specific naturally acquired IgG antibodies in plasma from both malaria negative and positive
children living in a high transmission area of Cameroon recognized all three recombinant phages. However, plasma
from children less than five years old contained significantly less plasma levels of antigen specific IgG antibodies.
Conclusion: Thus, the novel recombinant phages QβMSP3, QβUB05 and QβUB05-MSP3 can be used as a tool
for assessing natural or vaccine-induced antibody responses against malaria. The recombinant chimeric QβUB05-
MSP3 phage is validated as a multivalent antigen for tracking semi immunity to malaria.
Keywords: MSP3; UB05; UB05-MSP-3; RNA Coliphage Qβ;
Antigenicity; Hyper endemic and children
Abbreviation:
MSP3: Merozoite surface protein 3; P. falciparum: Plasmodium
falciparum; EBA140: Erythrocyte binding antigen 140; Rh2: Rhoptry
proteins 2; AU: Arbitrary units; MOI: Multiplicity of infection; LLIN:
Long lasting insecticide; IQR: Interquartile range; CNBR: Center for
Nano Biotechnology Research; 3D: Three-dimensional; BSA: Bovine
serum albumin
Introduction
Concerted global efforts have resulted into a significant reduction in
morbidity and mortality due to malaria. However the threat due to this
ancient scourge remains unrelenting as an estimated 216 million cases
and 455000 deaths were recorded in 2016 (World health organization,
2016). Malaria caused by Plasmodium falciparum (P. falciparum) is the
most common and virulent form of the disease especially in sub
Saharan Africa where most of the global casualties are recorded in
children and pregnant women [1]. Current strategies to eradicate the
disease are being limited by several factors including parasite genetic
diversity, resistance of vector to insecticide and parasite to drug
therapies [2-4]. This has resulted too many regions of malaria endemic
countries maintaining perennial high malaria transmission zones with
consequent significantly high illness burden. Persistent high disease
burden within these populations makes developing an effective malaria
vaccine the only viable option to stem out the disease.
The recently approved malaria vaccine Mosquirix which induces
sporozoites specific antibodies to prevent the malaria parasite from
infecting the liver [5,6] though limited in efficacy [7,8] provides a basis
upon which to further improve the efficacy of a global vaccine against
malaria. In addition, high concentrations of asexual stage antigen
specific antibodies have been associated with substantial reduction of
parasitaemia and clinical symptoms thereby high lighting their
importance in semi immunity to malaria [9]. This makes asexual blood
stage malaria vaccines desirable objectives for eliminating clinical
malaria. Since long term inhabitants of malaria endemic countries
acquire protection from symptomatic malaria following repeated
exposure to the malaria parasite [10,11] there is need to also probe
these immune responses for correlates of resistance to malaria.
Previously antibodies targeting several asexual stage antigens
including the merozoite surface antigens 1 (MSP1) and 3 (MSP3),
microneme proteins erythrocyte binding antigen 140 (EBA140) and
175 (EBA175) and rhoptry proteins 2 (Rh2), 5 (Rh5) and UB05 are
reported to protect children (5–14 years) from clinical malaria [12-14].
In this study, we have chosen an approach based on the display of
promising Plasmodium falciparum derived malaria antigens upon
surface of the RNA coliphage Qβ for effective presentation to the
immune system. The Merozoite surface protein 3 (MSP3) and UB05
are two malaria parasite blood-stage antigens validated as potential
malaria vaccine candidates following analysis of their role in protective
immunity in children and adults [14-17].
In order to circumvent the predominant antigen variability of the
N-terminal of 48-kDa MSP3 protein we targeted just the conserved C-
terminal aa of MSP-3 which has been demonstrated [16,18] to
contribute to semi-immunity to blood stage malaria in both children
and adult.
Immune responses targeting the conserved C-terminal 88 aa of
MSP-3 for example have been directly implicated in long term
protection [19] and strong reduction in incidence of clinical malaria
[20]. This is mainly because this region is not only conserved across
different parasite strains [21-23]; but equally possessed epitopes
confirmed to be targeted by antibodies associated with protection
[18,23]. Similarly UB05 antigen specific immune responses have been
reported as a potential marker of protective immunity against malaria
[14,24,25].
In this study we genetically engineered the malaria blood stage
immunogens UB05, MSP3 and their chimera UB05-MSP3 upon the
surface of the RNA coliphage β, then used the ensuing recombinant
phages to assess semi immunity to malaria in children in a high
malaria transmission region of Cameroon. Recombinant chimera
βUB05-MSP3 becomes necessary since malaria vaccines containing
more than one fusion antigen have been demonstrated to induce
effective immunity [24] resulting to protection against clinical malaria
in African children [26-28]. Since anti-UB05 and anti-MSP3
antibodies have each been incriminated with protection against
malaria this new antigen combinations might more reliably detect
antibody responses which are predictive of protective ability of the
immune system from clinical malaria.
Materials and Methods
Media used for bacteria culture and phages were purchased from
Fisher Scientific (Pittsburgh, PA). Restriction enzymes and T4 ligase
were purchased from New England BioLabs (Ipswich, MA). RbCl and
CaCl2 including other major reagents were purchased from Sigma-
Aldrich (St. Louis, MO). DNA preparation for clones screening and
PCR clean up kit was purchased from QIAGEN (Valencia, CA). IgG
Mouse monoclonal antibodies specific to C and N-terminal of UB05
and MSP3 proteins were purchased from Abmart (Xietu Road,
Shanghai). Horseradish peroxidase (HRP)-conjugated, mouse anti-
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human IgG, IgG1, IgG3 and gG4 antibodies were purchased from
Southern Biotech (Birmingham, USA).
Microorganisms
E. coli MC1016 (Invitrogen, Grand Island, NY) was used to grow
and maintain the plasmids. E. coli HB101 was used to grow and
maintain pQβ8ΔA1and their recombinant products. E. coli ATCC
23725 (K12) was used for phage production and titration. A control
plasmid, pQβΔA1, was also maintained and amplified with the same
cell.
Design and 3D structural modelling of the recombinant
QβMSP3, QβUB05 and QβUB05-MSP3 phages
Amino acid sequences for codon optimized MSP3, UB05 and
chimeric UB05-MSP3 immunogens were cloned in expression
cassettes as indicated in Figure 1. The expression cassettes were
analysed using the sequence analysis software DNA strider while
taking into consideration the secondary structure of the RNA of the
recombinant coliphage as previously reported [18,23]. The designed
MSP3, UBO5 and UBO5MSP3 regions included an SSGGG linker
flanked with the restriction site Not1 for cloning. The first PCR was
done by annealing and extending with primers UBO5-NotIF and
UB05-NotIR to obtain the UB05 insert. The MSP3 insert was amplified
with the primers MSP3-NotIF and MSP3-NotIR and similarly treated.
Using partially complementary primer designs, the products of the first
two PCR were used as a template in an overlap PCR to generate the
chimeric UB05-MSP3 inserts. Restriction enzyme site is bold and
underlined (Table 1). All primers were designed to maintain the
reading frame and important secondary structure of hybrid phage
RNA. The sequences for the minor coat protein A1 and engineered
proteins were modelled using the template based modelling using
Raptor X web server (doi: 10.1038/nprot.2012.085). The models were
then transformed to view the protein backbone and highlight the
secondary structures using MolGro molecular viewer. The structures
were next aligned to understand the differences among the protein
models.
UB05-NotIF:
5’ ttatGCGGCCGCAtgggcagccagattcagccgagccgctttctggatagcgcgatt
UB05-NotIR:
5’ ggtggcggccgcTTACTAtttttttttatcgcggttcaggcggttcgg
MSP3-NotIF:
5’ccacGCGGCCGCCgcaaaaccaaagaatatgcggaaaaagcgaaaaacgcgtatgaaaaagc
MSP3-NotIR:
5’ ccaatagcggccgcTTACTAttccagttcttcttcttcggtttcttccgcttcttcttctttttcatcc
Table 1: List of primers used to amplify the UB05 and MSP3 regions.
Cloning and production of recombinant MSP3, UB05 and
UB05MSP3 phages
The cloning vector pQβ8ΔA1 and the inserts including MSP3, UB05
and UB05-MSP3 were prepared and the recombinant plasmids
generated as previously reported in our group [29]. Confirmed
plasmids were sequenced to validate fusion and ensure that the inserts
were in frame at the end of the minor coat protein A1. Validated
positive clones were used to retransform E. coli HB 101 for phage
production.
Phage production and characterization
Validated clones were selected and inoculated into the nutrient
media (2YT), and allowed to grow at 37℃ for 4 hrs while shaking (150
rpm). Each culture was then scaled up to one litre of 2YT and allowed
to grow at 37℃ for 18 hrs while shaking (150 rpm). The resultant
recombinant phage was precipitated using 29 g of NaCl and 80 g of
polyethyleneglycol (PEG8000) and amplified using the indicator E. coli
strain K12. One percent of the fresh overnight culture of K12 on
nutrient media (TGY) was amplified at 37℃ while shaking (180 rpm)
for 3-5 hrs to reach an OD 600 of 0.6-0.8. Each recombinant phage was
inoculated to the culture at a multiplicity of two and incubated at 37℃
for 18 hrs on a racking platform (150 rpm). The recombinant phage
were produced and characterized as previously described in our group
[29].
Western blot analysis of recombinant QβMSP3, QβUB05 and
QβUB05-MSP3 phages for the expression of their respective
proteins
About 92.5 µl of each recombinant phage was mixed with 2.5 µl of
β-Mercaptoethanol and 5 µl SDS (20%) then incubated for 1 hr at
37℃. Then 100 µl of 2x Laemmli SDS buffer was added and further
incubated for 10 mins at 100℃. The samples were loaded in a 10%
polyacrylamide gel and allowed to run for 1 hr intervals at 30, 50 and
70 volts. The separated proteins were then transferred unto a
nitrocellulose membrane, blocked with 1x roti block and probed with
Plasma containing high titers of MSP3 and UB05 specific polyclonal
antibodies. Specific recognition of the immunogens was revealed with
Horse radish peroxidase-conjugated Mouse anti-human IgG (Southern
Biotech, Birmingham, USA) diluted 1:4000 in 1x roti block. Bound
conjugate was detected using 1-step ultra TMB blotting solution
(Thermoscientific, USA) and the HRP reaction stopped by washing
with molecular grade pure water.
Reactivity of the recombinant phages QβUB05, QβMSP3 and
QβUB05MSP3 with monoclonal antibodies targeting the N-
and C-terminal regions of UB05 and MSP3 antigens
The recombinant phages including QβUB05, QβMSP3 and
QβUB05-MSP3 were diluted seperately in PBS so that 100 µl
containing 107 phage particles were added/well to high binding 96-
well flat bottom microsorp (Thermo Fisher Scientific) ELISA plates
and incubated overnight at 4℃. The following day, plates were washed
3x with PBST (PBS with 0.05% Tween-20) and blocked either with 3%
BSA or 1x Roti block (Carl ROTH, Karlsruhe, Germany) for one hour
at 37℃. The coated plates were then probed with graded doses of
monoclonal antibodies X-Q38G73-N (anti-UB05 N-terminal), X-
Q38G73-C (anti-UB05 C-terminal), X-Q0KGH2-M (anti-MSP3 M-
terminal) and X-Q0KGH2-C (anti-MSP3 C-terminal) diluted in 2%
BSA at the concentrations 1000, 100, 10, 1 and 0.1 ng/ml. 100 µl of the
diluted antibodies was added per well and incubated for two hours at
37℃. Unbound antibodies were removed by washing 5x (198 µl/well)
with PBST. Reactivity of the monoclonal antibodies with the
recombinant phages were probed with Horse radish peroxidase-
conjugated Goat anti-mouse IgG (Southern Biotech, Birmingham,
USA) diluted at 1:4000 in 0.1x Roti block. Bound conjugate was
detected using ABTS substrate and the HRP reaction stopped by
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adding 100 µl a stop solution according to the manufacturer’s protocol
(Southern Biotech, Birmingham, USA). The colorimetric signal was
measured at 405 nm using a multiscan FC microplate reader (Thermo
Fisher Scientific, USA).
Study site and population
The study was conducted in Bikop, a rural community 48km away
from Yaounde the capital city of Cameroon. This is a region with
intense perennial malaria driven by a dominant P. falciparum
infection. A total of 348 children aged between 2 to 15 years both
positive and negative for malaria by rapid diagnostic test (SD Bioline
Malaria Ag p.f./pan, Ingbert Germany) and microscopy were recruited
for this study.
Plasma sample collection and processing
Samples were collected from consented participants from November
2014 to November 2017. Blood samples were collected into 4 ml plastic
Vacuum blood spray-coated K2EDTA tubes called Vacutest
(Vacutestkirma, Italy). All samples were stored at room temperature
and processed within 4 hrs of collection. To obtain plasma, samples
were centrifuged at 2,000 rpm for 10 min at 4℃. The plasma fraction
was harvested sterile under a biosafety hood, aliquoted in small, single-
use volumes and stored at -20℃ until use. The plasma obtained from
participants was heat inactivated for 30 minutes at 56℃ prior to ELISA
assay.
Reactivity of the recombinant phages QβUB05, QβMSP3 and
QβUB05-MSP3 with plasma from children
The plasma levels of antibodies specific to the malaria immunogens
UB05, MSP3 and UB05-MSP3 were determined by ELISA assay.
Briefly high binding ELISA plates were coated with 107 particles/well
of each recombinant phage and incubated overnight at 4℃ as
described above. The following day, Plates were washed 3x with PBST
(PBS containing 0.05% Tween 20) and blocked with 3% Bovine serum
albumin (BSA) in PBST for one hour at 37℃. Heat inactivated plasma
from both malaria positive and negative children were diluted serially
in PBS then 100 µl/well added in triplicate and incubated for two hours
at 37℃. The plates were washed 5x (198 µl/well) with PBST after which
the bound antibodies were probed with the peroxidase-conjugated
mouse anti-human IgG (Southern Biotech, Birmingham, USA) diluted
1:2000 in PBS. Bound conjugate was detected using ABTS substrate
and stop solution according to the manufacturer’s protocol (southern
biotech, Birmingham USA). The colorimetric signal was measured at
405 nm using a multiscan FC microplate reader (Thermo Fisher
Scientific, USA). ELISA titre was expressed as arbitrary units (AU)
based on five human samples with high anti-UBO5-MSP3 specific IgG
antibodies.
Statistical analysis
Data analysis was performed with Graphpad Prism Software version
6.1. First a one way ANOVA was used to assess if there were
differences between the means. The Tukey multiple comparison test
and kruskal-Wallis were then used to determine which of the means
were different. Statistical significance was confirmed when P<0.05.
Results
Design and generation of pQβUB05, pQβMSP3 and
pQβUB05-MSP3 plasmid vector variants
We previously demonstrated that up to 300 bp of foreign sequences
could be inserted into the minor coat protein gene A1 of Qβ phage,
without affecting its functionality [29-31]. Similarly the plasmids
pQβΔA1 was used to generate expression cassettes for UB05
(pQβUB05), MSP3 (pQβMSP3) and chimeric UB05-MSP3
(pQβUB05-MSP3) (Figure 1C to 1E). The sequences of codon
optimized UB05 (Genbank accession Number DQ235690) and 96
amino acids (146-243) derived from the conserved C-terminal region
of P. falciparum MSP3 (Genbank accession number AMM75921.1)
were amplified from a previously generated codon optimized construct
and clone in the expression cassette (Figure 1A). UB05 and MSP3
regions were amplified with the primers indicated in Table 1 to contain
the Not1 restriction sites indicated in bold for subsequent cloning. In
S1a data is shown for the PCR amplification of the different antigens
alongside the cloning vectors. The secondary structure of all
recombinant phage RNA was analysed to ensure that all major features
necessary for recombinant phage expression were conserved.
Figure 1: Schema of the recombinant QβMSP3, QβUB05 and
QβUB05-MSP3 sequences. In (A) schema of pCMV
HD83.UBO5MSP3 plasmid map from where UB05 and MSP3
antigens were amplified using PCR. In (B) schema of Qβ indicating
the deletion in the C-terminal end of the minor coat protein A1
where the chimeric UB05-MSP3 region inserted. In (C) amino acid
sequence of the recombinant phage QβUB05-MSP3. In (D) and (E)
amino acid sequences of the recombinant phages QβUBO5 and
QβMSP3 respectively.
3D modelling to determine the localization of the inserted
UB05 and MSP3 regions within the minor coat protein A1
Next using knowledge of the confirm three dimensional structures
of mutant A1 protein fused with various peptides as previously
demonstrated in our consortium [29,31] we conducted a comparative
three dimensional modelling of the three newly fused proteins
including UB05, MSP3 and UB05-MSP3. In this regards their
respective amino acid sequences were used together with minor coat
protein A1 of the coliphage Qβ for a three-dimensional (3D) modelling
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as previously reported in our group [29]. The resultant derivatives
including the wild type, Qβ MSP3, QβUB05 and QβUB05-MSP3
respectively are shown in Figure 2. The 3D structural modelling
revealed that the UB05, MSP3 and UB05-MSP3 regions were displayed
respectively in the C-terminal end of the minor coat protein A1 as
indicated by corresponding changes in their conformation when
compared to the wild type minor coat protein A1. This was in contrast
to the N terminus of the minor coat protein A1 protein, which
apparently was not significantly changed conserving its α-helixes and
β-sheets structurally in all models. With respect to structural homology
with wild type A1 protein the modification in the C-terminal of the
modified minor coat protein.
Figure 2: Three-dimensional structures predicted for the wild type
and engineered Qβ minor coat protein A1. (A) Qβ wild type. (B)
QβMSP3. (C) QβUB05. (D) QβUB05-MSP3. UB05 and MSP3
highlighted in ball and stick rendering at the C terminal region of
the protein. N indicates the N terminus of the minor coat protein
A1; red and blue coloured structures indicate α-helix and β-sheets,
respectively.
A1 seemed to have impacted upon the rotation of its N-terminus
(Figure 2B to 2D). Never the less the UB05, MSP3 and UB05-MSP3
proteins were confirmed to be exposed at the C-terminus around the
β-sheets and between the N-terminal domains. Further comparative
structural modelling of the C-terminus of the recombinant minor coat
protein A1; situated it to the outer surface of the capsid as shown in the
ball and stick depiction (Figure 2B to 2D). This was similar to previous
three-dimensional models of A1 fused proteins reported in our group
which had been demonstrated to efficiently display surface accessible
peptides [29,31].
Recombinant Phage production strategy and genetic
characterization
Due to the fact that an insertion of a foreign antigen upon the
surface of Qβ generally results to a significant reduction in
recombinant phages titres we adopted methods previously optimized
by our group to ensure adequate phage yield [29]. Briefly the
recombinant phages obtained after the first round of amplification in
one litre of culture medium, were precipitated and suspended in 10ml
of media followed by 3 more rounds of amplification each with an
inoculating multiplicity of infection (MOI) of 3. To improve
recombinant phage yield, E coli Q13 the natural host of the phage Qβ
was used instead of E. coli HB101 as previously reported [29]. This
resulted into a significant increase (P<0.0001) in the yield of the
resultant recombinant phages (1014 pfu/ml compared to 108 pfu/ml)
which were then used for subsequent analysis. An analytical gel
electrophoresis for the selection of recombinant QβUB05-MSP3 phage
is shown in S1b. The recombinant phages were characterized as
reported previously [29]. Thus, the insertion of the MSP3, UB05 and
UB05MSP3 regions into the minor coat protein A1 of the coliphage Qβ
permits efficient surface display of the MSP3, UB05 and UB05-MSP3
antigens without affecting viability and infectivity.
Antibodies Epitopes
X-Q0KGH2-M
(MSP3 M-terminal)
AKDDAEKSSKAD
KADSISTKTKEY
KDKENISKENDD
X-Q0KGH2-C
(MSP3 C-terminal)
DVLDEKEEEAEETE
EISEDEEEEEEEEE
QSNENNDQKKDMEA
X-Q38G73-N
(UB05 N-terminal)
MGSQIQPSRFLDSA
MMSHESKLFNNKLS
RLFPFKTFEYNLTH
X-Q38G73-C
(UB05 C-terminal)
LSLKPDSVSSKYGL
KDSRKPQGKDDAHK
GDEDPNRLNRDKKK
Table 2: Monoclonal antibodies and their respective epitopes.
Reactivity of the recombinant phages QβMSP3, QβUB05 and
QβUB05-MSP3 with monoclonal antibodies targeting the
N- ,M- and C- terminal regions of the inserted proteins
The recombinant phages QβUB05, QβMSP3 and QβUB05-MSP3
were assessed for reactivity with monoclonal antibodies recognizing
the N-, M- and C-terminal regions of either UB05 or MSP3 (Table 2).
Briefly ELISA plates were coated with 107 pfu/well of QβMSP3,
QβUB05 and QβUB05-MSP3 respectively as described in materials
and methods then probed with graded doses of each monoclonal
antibody. As shown in figure 3A the recombinant phage QβUB05
reacted specifically with the monoclonal antibodies X-Q38G73-N
(anti-UB05 N-terminal) and X-Q38G73-C (anti-UB05 C-terminal)
while in figure 3B recombinant phage QβMSP3 reacted exclusively
only with monoclonal antibodies X-Q0KGH2-M (anti-MSP3 M-
terminal sequences in the middle) and X-Q0KGH2-C (anti-MSP-3 C-
terminal) in a dose dependent manner. Similarly the recombinant
phage QβUB05-MSP3 (Figure 3C) displaying the chimeric UB05-
MSP3 antigen reacted with all four monoclonal antibodies in a dose
dependent manner clearly indicating that both immunogens were built
upon the surface of the recombinant phage. Comparative to the anti-
C-terminal portion targeting monoclonal antibodies, the N-terminal
region of each insert reacted more strongly with their corresponding
antibodies for all three recombinant phages. The specific recognition of
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all three recombinant phages by malaria antigen specific antibodies
was further confirmed in western blot analysis (Figure 3D).
Figure 3: Western blot analysis and antigenicity of the recombinant
QβMSP3, QβUB05 and QβUB05-MSP3 phages with monoclonal
antibodies targeting the N and C-terminals of the inserts. In (A) (B)
& (C) binding of recombinant QβMSP3, QβUB05 and QβUB05-
MSP3 phages with N and C-terminal targeting monoclonal
antibodies. Anti-UB05 N-terminal (brown line), anti-UB05 C-
terminal (black line), anti-MSP3 M-terminal (red line) and anti-
MSP3 C-terminal (blue line). In (A) reactivity of graded
concentrations of anti-UB05 N-terminal (X-Q38G73-N) and anti-
UB05 C-terminal (X-Q38G73-C) monoclonal antibodies with the
recombinant QβUB05 phage. In (B) reactivity of graded doses of
anti-MSP3 M-terminal (X-Q0KGH2-M) and anti-MSP3 C-terminal
(X-Q0KGH2-C) monoclonal antibodies with recombinant QβMSP3
phage. In (C) reactivity of graded doses of all four monoclonal
antibodies with recombinant QβUB05-MSP3 phage. In (D) data is
shown for the western blot analysis of the recombinant phages. Lane
1 is a Mock (QβMPER), lane 2 is recombinant QβUB05-MSP3, lane
3 is recombinant QβUB05, lane 4 is recombinant QβMSP3 and lane
5 is the protein marker.
Study population characteristics
A total of 348 children were enrolled after written informed consent
as described in materials and methods. The children were from a
perennial high malaria transmission region of Cameroon 48 km away
from the capital City. This implies that the children were exposed to
the same rate of mosquito bite during their life. The age range of
participants was between 2 to 15 years old. Amongst the children
enrolled 224 were diagnosed malaria positive with Plasmodium
falciparum accounting for 82% of cases and the rest being a mixture
with other malaria parasite strains (P. falciparum mixed with either P.
ovale or P. malariae). Both malaria positive and negative children were
stratified into three age categories consisting of two to four years (<5),
six to ten years and eleven to fifteen years (Table 3).
Malaria positive
(n=224)
Malaria negative
(n=124)
Gender n (%) 
Male 129 (58) 62 (50)
Female 95 (42) 62 (50)
Age n(IQR)
˂5 years 67 (2-5) 43 (3-5)
6-10 years 117 (6-10) 55 (6-10)
˃10 years 40 (11-15) 26 (11-13)
Temperature ℃ mean(IQR)
˂5 years 36.32 (36-37) 36.54 (36-38)
6-10 years 36.41 (36-37) 36.13 (35-37)
˃10 years 36.14 (35-37) 36 (35-37)
LLIN = Yes n (%)
˂5 years 39 (58) 30 (70)
6-10 years 67 (57) 39 (71
˃10 years 23 (40) 17 (65)
Haemoglobin g/dL mean (IQR)
˂5 years 9.2 (4.7-15.8) 12.44 (4.20-15.80)
6-10 years 10.35 (6.6-15.2) 11.38 (6.9-13.20)
˃10 years 11.73 (9.8-14.9) 12.52 (10.5-15.1)
LLIN: long lasting insecticide, IQR: interquartile range
Table 3: Study population characteristics.
Comparative analysis of the antigenicity of the recombinant
phages QβUB05, QβMSP3 and QβUB05-MSP3 for reactivity
with polyclonal antibodies in plasma from malaria negative
children
Since antibodies specific to multiple P. falciparum antigens have
been associated with semi immunity in children [32] we compared the
three recombinant phages including QβUB05, QβMSP3 and their
chimera QβUB05-MSP3 with respect to reactivity with polyclonal
antibodies in plasma from malaria negative children. In figure 4
whereas all three recombinant phages reacted strongly with polyclonal
plasma in all the three age groups, children older than ten years
showed the highest plasma levels of antigen specific IgG antibodies. In
contrast children less than five years showed the least plasma levels of
antigen specific IgG antibodies (compare Figure 4A, 4B and 4C) which
were significantly less (P<0.0001) when compared to values in plasma
from children greater than 10 years old group. IgG antibody level of
children five to ten years old was superior to levels in children less than
5 years old. However these antibody levels were significantly higher
only for the recombinant phage QβUB05-MSP3 (P<0.0045).
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Figure 4: Antigenicity of the recombinant phages QβMSP3,
QβUB05 and QβUB05-MSP3 in plasma from malaria negative
children. Plasma of malaria negative participants was tested for
reactivity with the different recombinant phages including
QβMSP3, QβUB05 and QβUB05MSP3. In (A) data is shown for the
reactivity of the recombinant phage QβMSP3 with plasma from
participants of different age groups. In (B) and (C) same as in (A)
but here the antigens used were the recombinant phages QβUB05
and QβUB05-MSP3 respectively. Here, plasma from children older
than 10 years was significantly more reactive with the recombinant
phages (P<0.0001) than in the other age groups.
Similarly antigen specific antibody levels in children greater than 10
years old were significantly higher than values in the 5-10 age groups
for both QβUB05 and QβMSP3. On the other hand reactivity with
QβUB05-MSP3 was not significantly different between the 5-10 and
the greater than 10 years old age groups. Overall, the antigenicity of the
phage displayed malaria parasite derived antigens was dependent upon
the age of the participants increasing correspondingly with age.
However the recombinant phage QβUB05-MSP3 proved superior in
distinguishing the participants into those who have significantly high
antibody levels (children older than five years) and those with less
antibody levels (children less than five years old). Thus the
recombinant phage QβUB05-MSP3 could be used to track antibody
responses in malaria negative children.
Reactivity of the recombinant phages QβUB05, QβMSP3 and
QβUB05-MSP3 with polyclonal antibodies in plasma from
malaria positive children
Similarly we also compared the reactivity of the three recombinant
phages QβUB05, QβMSP3 and QβUB05-MSP3 with polyclonal
antibodies in plasma from malaria positive children. During acute
malaria individuals older than five years showed comparatively higher
antibody levels. However with respect to children 5-10 years old the
antibody levels were not significantly higher for all the recombinant
phages including QβUB05 (P<0.08), QβMSP3 (P<0.0082) and
QβUB05-MSP3 (P<0.063) respectively. As shown in figure 5A to 5C in
children older than 10 years significantly higher antibody levels were
observed for QβMSP3 (P<0.0041), QβUB05 (P<0.0120) and QβUB05-
MSP3 (P<0.0021) respectively. However between the groups of
children 5-10 and greater than 10 years old, no difference is observed
in the antibody levels for all the recombinant phages including
QβUB05 (P<0.4518) QβMSP3 (P<0.6204) and QβUB05-MSP3
(P<0.4412). Thus during acute malaria all recombinant phages were
able to detect antigen specific antibodies in all the age group with the
age of the participants being the deciding factor.
Discussion
In this study we have engineered Plasmodium falciparum derived
UB05, MSP3 and also a chimera of the two antigens; UB05-MSP3
upon the surface of the RNA coliphage Qβ. Surface engineering of Qβ
allowed us to display as a single unit UB05 and MSP3 upon the surface
of the recombinant phage as a bivalent malaria vaccine candidate. All
immunogens were built upon the recombinant Qβ phage by genetically
inserting their corresponding sequences into an optimized C-terminal
part of its A1 protein as previously described by our group. Genetically
linking of promising immunogens to the surface of Qβ virus like
particles allows them to be displayed at high density [29,31,33]. This
high-density display, as previously reported in our group in turn can
dramatically enhance antigenicity and immunogenicity of the desired
immunogen [29]. This organized display of antigen upon the surface of
recombinant Qβ phage particle has also been demonstrated by [34] in
the context of tumor vaccine development. To boost the
immunogenicity of malaria vaccines Qβ virus like particles has also
previously been chemically conjugated to CSP [35] or Pfs25 [36].
Once displayed upon the recombinant phage the chimeric QβUB05-
MSP3 must maintain its native form to ensure that immunologically
relevant epitopes are available for immune recognition. Therefore in
three dimensional modelling and transmission electron microscopy
(data not shown) we could confirm that the immunogens were
exposed upon the surface of all the recombinant phages. In ELISA
assay using defined epitopes targeting monoclonal antibodies we
demonstrated that all recombinant phages were strongly recognized by
their respective N-, M- and C-terminal specific monoclonal antibodies.
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Our consortium has previously optimized strategies to enhance the
yield of recombinant Qβ phages [29].
Figure 5: Antigenicity of the recombinant phages QβMSP3,
QβUB05 and QβUB05MSP3 in plasma from malaria positive
children. Plasma of malaria positive participants was tested for
reactivity with the different recombinant phages including
QβMSP3, QβUB05 and QβUB05MSP3. In (A) data is shown for the
reactivity of the recombinant phage QβMSP3 with children grouped
according to different age groups. In (B) and (C) same as in (A) but
here the antigens used were recombinant QβUB05 and
QβUB05MSP3 respectively. Here, plasma of all children older than
five years were significantly more reactive with recombinant phages
(P<0.01) than samples from children less than 5 years old.
Ease of production allows cheap and rapid scale up for large scale
production. Qβ is attractive as a vaccine vector because recombinant
Qβ is devoid of bacteriophage genetic information and is neither
infectious nor capable of replicating. Moreover during recombinant
gene expression E.coli RNA which is potent TLR7/8 ligands gets
packaged in the phage particles and thus could activate the immune
system. In addition to efficient immune-stimulatory properties Qβ
recombinant phage display has a number of desirable features for
vaccine development including stability, safety, rapid and cheap
manufacture.
However here we wanted to test whether antigenicity of both MSP3
and UB05 could be further improved by genetically incorporating
them as a chimera upon the surface of Qβ. The recombinant phage
QβUB05-MSP3 was tested side by side with both QβUB05 and
QβMSP3 for their antigenicity in plasma from children living in a high
malaria transmission region of Cameroon. In a comparative analysis of
the recognition of the recombinant phages QβUB05, QβMSP3 and
QβUB05-MSP3; we observed for both malaria positive and negative
children greater levels of antigen-specific IgG antibodies in the plasma
of those older than 10 years relative to children less than five years.
Antibody levels in plasma of 5-10 years old malaria negative children
was also significantly higher (p=0.045) for the recombinant phages
QβUB05-MSP3 relative to their counterpart less than 5 years old. This
implies that QβUB05-MSP3 could be used not only to track antibody
levels in children but can be a potential vaccine candidate for boosting
such responses in these children.
People with naturally acquired immunity to malaria produce
antibodies specific to several parasite antigens which have been
demonstrated to play a role in their resistance to clinical disease and
parasitaemia [14,24,32,37]. In this regards protective immunity
mediated especially by asexual blood stage antigens like MSP3 or UB05
could either mean just the absence of symptomatic malaria but
underlying parasitaemia or the complete absence of both symptomatic
malaria and parasitaemia. In this study most of children diagnosed
positive for malaria by point of care kit and microscopy were all
parasitaemic without clinical symptoms. This is probably due to the
fact that participants were from a high malaria transmission region
where people including children can gain protection from severe
disease early on in life as a result of frequent exposure to the malaria
parasite. High concentrations of antibodies specific to a number of
asexual blood stage antigens including MSP1-3, AMA-1, UB05, MSP3
have been associated with protective immunity against malaria [38].
However this may not always be true as in children in Mali the number
of antigens recognized was more relevant in protection than antibody
titers [32].
In this study children less than five years irrespective of their
malaria status showed significantly less anigen specific antibody levels
than their counterparts older than five years. This is probably due to
age linked limitted exposure to the malaria parasite comparared to
older children who probably must have experienced far more
exposures. However no clear cut distinction could be made between
protective immune responses to malaria and those resulting from
exposure to the parasite during clinical malaria. In both malaria
positive and negative participants, antibody levels increased
concurrently with age probably as a result of accumulating antibody
responses to different circulating Plasmodium falciparum strains
within this high malaria transmision zone as previously reported for
other regions.
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Conclusion
The recombinant QβMSP3, QβUB05 and QβUB05-MSP3 phages
presented here were antigenic for monoclonal antibodies targeting
their N and C-terminal regions respectively. They all differentially
detected blood stage antigen targeting antibodies in children below
and above five years old. Thus designing and validating novel
approaches for the study of human malaria especially in children who
are the most susceptible in high transmission zones could usher in new
management strategies that would limit mortality and morbidity.
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